We are live on ! Find out more
VU

Valence8 US Portfolio holdings

AUM $286M
1-Year Est. Return 22.37%
This Fund
S&P 500
This Quarter Est. Return
+6.13%
1 Year Est. Return
+22.37%
3 Year Est. Return
+53.91%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$241M
AUM Growth
+$49.2M
Cap. Flow
+$37.5M
Cap. Flow %
15.54%
Top 10 Hldgs %
93.09%
Holding
62
New
53
Increased
3
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
QUAL icon
iShares MSCI USA Quality Factor ETF
QUAL
+$6.32M
2
QQQ icon
Invesco QQQ Trust
QQQ
+$5.41M
3
IQLT icon
iShares MSCI Intl Quality Factor ETF
IQLT
+$5.34M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$983K
5
BMY icon
Bristol-Myers Squibb
BMY
+$834K

Top Sells

Rank Stock Value
1
VTV icon
Vanguard Value ETF
VTV
+$565K
2
EWU icon
iShares MSCI United Kingdom ETF
EWU
+$275K
3
XLU icon
State Street Utilities Select Sector SPDR ETF
XLU
+$271K
4
XLP icon
State Street Consumer Staples Select Sector SPDR ETF
XLP
+$244K

Sector Composition

Rank Sector Weight
1 Healthcare 4.12%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
26
DELISTED
Nuvalent
NUVL
$421K 0.17%
+4,115
New +$341K
FLNA
27
PUT
Filana Therapeutics
FLNA
$51.2M
$415K 0.17%
+14,100
New +$325K
RARE icon
28
CALL
Ultragenyx Pharmaceutical
RARE
$2.88B
$383K 0.16%
+6,900
New +$351K
APLS
29
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$378K 0.16%
+13,100
New +$485K
JANX icon
30
Janux Therapeutics
JANX
$992M
$357K 0.15%
+7,857
New +$342K
AVDL
31
CALL
DELISTED
Avadel Pharmaceuticals
AVDL
$344K 0.14%
+26,200
New +$399K
CRNX icon
32
Crinetics Pharmaceuticals
CRNX
$8.88B
$342K 0.14%
+6,684
New +$345K
TYRA icon
33
Tyra Biosciences
TYRA
$1.91B
$310K 0.13%
+13,188
New +$277K
APGE icon
34
Apogee Therapeutics
APGE
$10.1B
$308K 0.13%
+5,240
New +$251K
VRDN icon
35
CALL
Viridian Therapeutics
VRDN
$1.99B
$298K 0.12%
+13,100
New +$214K
PCVX icon
36
Vaxcyte
PCVX
$8.12B
$282K 0.12%
+2,468
New +$222K
MRNA icon
37
CALL
Moderna
MRNA
$24.5B
$274K 0.11%
+4,100
New +$376K
NTLA icon
38
Intellia Therapeutics
NTLA
$1.59B
$268K 0.11%
+13,020
New +$300K
VIR icon
39
Vir Biotechnology
VIR
$1.59B
$252K 0.1%
+33,650
New +$292K
BPMC
40
DELISTED
Blueprint Medicines
BPMC
$242K 0.1%
+2,618
New +$260K
RARE icon
41
Ultragenyx Pharmaceutical
RARE
$2.88B
$236K 0.1%
+4,241
New +$216K
CLDX icon
42
PUT
Celldex Therapeutics
CLDX
$2.77B
$221K 0.09%
+6,500
New +$248K
ENTA icon
43
Enanta Pharmaceuticals
ENTA
$400M
$207K 0.09%
+19,939
New +$261K
RLAY icon
44
Relay Therapeutics
RLAY
$4.34B
$185K 0.08%
+26,200
New +$196K
APLT
45
CALL
DELISTED
Applied Therapeutics
APLT
$173K 0.07%
+20,300
New +$120K
ALT icon
46
CALL
Altimmune
ALT
$558M
$161K 0.07%
+26,200
New +$177K
ZVRA icon
47
Zevra Therapeutics
ZVRA
$755M
$150K 0.06%
+21,596
New +$147K
ALT icon
48
PUT
Altimmune
ALT
$558M
$144K 0.06%
+23,500
New +$159K
ERAS icon
49
Erasca
ERAS
$6.65B
$128K 0.05%
+46,923
New +$132K
IOVA icon
50
CALL
Iovance Biotherapeutics
IOVA
$2.23B
$123K 0.05%
+13,100
New +$124K
1
2
3

Similar funds

A
Argentarii Cincinnati, Ohio $286M AUM 32.04% 1-Year Est. Return
MC
Muzinich & Co New York $286M AUM 21.05% 1-Year Est. Return
IRAG
Investment Research & Advisory Group Atlanta, Georgia $286M AUM 19.21% 1-Year Est. Return
4WM
44 Wealth Management Eugene, Oregon $286M AUM 18.78% 1-Year Est. Return
MAG
Mayfair Advisory Group Birmingham, Alabama $286M AUM 19.6% 1-Year Est. Return
HMP
HS Management Partners New York $286M AUM 2.97% 1-Year Est. Return
SIIL
Sinvest Investments II Ltd Nassau, New Providence $286M AUM
LCM
Leisure Capital Management Costa Mesa, California $286M AUM 26.75% 1-Year Est. Return

Valence8 US's Q3 2024 Portfolio in Review

As of Q3 2024, Valence8 US held 62 positions worth $241M, up 26% from $192M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Valence8 US deployed $37.5M of net new capital in Q3 2024, opening 53 new positions and adding to 3 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 8,969 shares worth $999K.

By sector, the portfolio is most concentrated in Healthcare at 4.1% of assets, followed by Financials.

On the sell side, the largest reduction was Vanguard Value ETF, an estimated $565K trimmed.

  • Valence8 US's largest Q3 2024 buy was Jazz Pharmaceuticals: 8,969 shares worth $999K.
  • Valence8 US added most to iShares MSCI USA Quality Factor ETF in Q3 2024, an estimated $6.32M increase.
  • Valence8 US's biggest Q3 2024 reduction was Vanguard Value ETF, cutting an estimated $565K.
  • Valence8 US's ten largest holdings make up 93% of its $241M portfolio in Q3 2024.
  • Valence8 US opened 53 new positions and closed 0 in Q3 2024.
  • Valence8 US's portfolio value rose 26% quarter-over-quarter to $241M.

Based on Valence8 US's 13F filing for Q3 2024, filed 12 Nov 2024.